全文获取类型
收费全文 | 31013篇 |
免费 | 2574篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 533篇 |
儿科学 | 1246篇 |
妇产科学 | 1011篇 |
基础医学 | 4221篇 |
口腔科学 | 832篇 |
临床医学 | 2701篇 |
内科学 | 7173篇 |
皮肤病学 | 741篇 |
神经病学 | 3226篇 |
特种医学 | 988篇 |
外国民族医学 | 3篇 |
外科学 | 3880篇 |
综合类 | 533篇 |
一般理论 | 43篇 |
预防医学 | 2272篇 |
眼科学 | 628篇 |
药学 | 1751篇 |
中国医学 | 8篇 |
肿瘤学 | 1869篇 |
出版年
2021年 | 369篇 |
2020年 | 269篇 |
2019年 | 452篇 |
2018年 | 501篇 |
2017年 | 360篇 |
2016年 | 401篇 |
2015年 | 459篇 |
2014年 | 642篇 |
2013年 | 968篇 |
2012年 | 1263篇 |
2011年 | 1334篇 |
2010年 | 786篇 |
2009年 | 679篇 |
2008年 | 1208篇 |
2007年 | 1302篇 |
2006年 | 1298篇 |
2005年 | 1226篇 |
2004年 | 1225篇 |
2003年 | 1120篇 |
2002年 | 1182篇 |
2001年 | 1088篇 |
2000年 | 1157篇 |
1999年 | 955篇 |
1998年 | 327篇 |
1997年 | 273篇 |
1996年 | 279篇 |
1995年 | 291篇 |
1994年 | 282篇 |
1993年 | 302篇 |
1992年 | 860篇 |
1991年 | 804篇 |
1990年 | 680篇 |
1989年 | 725篇 |
1988年 | 675篇 |
1987年 | 705篇 |
1986年 | 650篇 |
1985年 | 674篇 |
1984年 | 536篇 |
1983年 | 460篇 |
1982年 | 293篇 |
1980年 | 256篇 |
1979年 | 452篇 |
1978年 | 303篇 |
1977年 | 256篇 |
1976年 | 276篇 |
1975年 | 263篇 |
1974年 | 296篇 |
1973年 | 293篇 |
1972年 | 266篇 |
1971年 | 260篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Osnat Bairey MD Alisa Taliansky MD Amir Glik MD Alexandra Amiel MD Shlomit Yust-Katz MD Ronit Gurion MD Miri Zektser MD Tzvika Porges MD Nadav Sarid MD Netanel A. Horowitz MD Tzahala Tzuk Shina MD Eyal Lebel MD Amos Cohen MD Karyn Revital Geiger MD Pia Raanani MD Ofir Wolach MD Tali Siegal MD 《Cancer》2023,129(24):3905-3914
2.
3.
Julia H. Vermylen Gordon J. Wood Elaine R. Cohen Jeffrey H. Barsuk William C. McGaghie Diane B. Wayne 《Journal of pain and symptom management》2019,57(3):682-687
Introduction
Physician communication impacts patient outcomes. However, communication skills, especially around difficult conversations, remain suboptimal, and there is no clear way to determine the validity of entrustment decisions. The aims of this study were to 1) describe the development of a simulation-based mastery learning (SBML) curriculum for breaking bad news (BBN) conversation skills and 2) set a defensible minimum passing standard (MPS) to ensure uniform skill acquisition among learners.Innovation
An SBML BBN curriculum was developed for fourth-year medical students. An assessment tool was created to evaluate the acquisition of skills involved in a BBN conversation. Pilot testing was completed to confirm improvement in skill acquisition and set the MPS.Outcomes
A BBN assessment tool containing a 15-item checklist and six scaled items was developed. Students' checklist performance improved significantly at post-test compared to baseline (mean 65.33%, SD = 12.09% vs mean 88.67%, SD = 9.45%, P < 0.001). Students were also significantly more likely to have at least a score of 4 (on a five-point scale) for the six scaled questions at post-test. The MPS was set at 80%, requiring a score of 12 items on the checklist and at least 4 of 5 for each scaled item. Using the MPS, 30% of students would require additional training after post-testing.Comments
We developed a SBML curriculum with a comprehensive assessment of BBN skills and a defensible competency standard. Future efforts will expand the mastery model to larger cohorts and assess the impact of rigorous education on patient care outcomes. 相似文献4.
Carine Cohen Edson D. Moreira Homero Nañez Jeyaseelan P. Nachiappan Catherine Huoi Joshua Nealon Elsa Sarti Esteban Puentes-Rosas Annick Moureau Alena Khromava 《Vaccine》2019,37(13):1868-1875
Background
The background incidence of viscerotropic- (VLD) and neurotropic-like disease (NLD) unrelated to immunization in dengue-endemic countries is currently unknown.Methods
This retrospective population-based analysis estimated crude and standardized incidences of VLD and NLD in twelve hospitals in Brazil (n?=?3), Mexico (n?=?3), and Malaysia (n?=?6) over a 1-year period before the introduction of the tetravalent dengue vaccine. Catchment areas were estimated using publicly available population census information and administrative data. The denominator population for incidence rates was calculated, and sensitivity analyses assessed the impact of important assumptions.Results
Total cases adjudicated as definite VLD were 5, 57, and 56 in Brazil, Mexico, and Malaysia, respectively. Total cases adjudicated as definite NLD were 103, 29, and 26 in Brazil, Mexico, and Malaysia, respectively. Crude incidence rates of cases adjudicated as definite VLD in Brazil, Mexico, and Malaysia were 1.17, 2.60, and 1.48 per 100,000 person-years, respectively. Crude incidence rates of cases adjudicated as definite NLD in Brazil, Mexico, and Malaysia were 4.45, 1.32, and 0.69 per 100,000 person-years, respectively.Conclusions
Background incidence estimates of VLD and NLD obtained in Mexico, Brazil, and Malaysia could provide context for cases occurring after the introduction of the tetravalent dengue vaccine. 相似文献5.
Julia Thornton Snider Jesse Sussell Mahlet Gizaw Tebeka Alicia Gonzalez Joshua T. Cohen Peter Neumann 《Value in health》2019,22(3):332-339
Background
Payers frequently rely on budget impact model (BIM) results to help determine drug coverage policy and its effect on their bottom line. It is unclear whether BIMs typically overestimate or underestimate real-world budget impact.Objective
We examined how different modeling assumptions influenced the results of 6 BIMs from the Institute for Clinical and Economic Review (ICER).Study Design
Retrospective analysis of pharmaceutical sales data.Methods
From ICER reports issued before 2016, we collected estimates of 3 BIM outputs: aggregate therapy cost (ie, cost to treat the patient population with a particular therapy), therapy uptake, and price. We compared these against real-world estimates that we generated using drug sales data. We considered 2 classes of BIM estimates: those forecasting future uptake of new agents, which assumed “unmanaged uptake,” and those describing the contemporaneous market state (ie, estimates of current, managed uptake and budget impact for compounds already on the market).Results
Differences between ICER's estimates and our own were largest for forecasted studies. Here, ICER's uptake estimates exceeded real-world estimates by factors ranging from 7.4 (sacubitril/valsartan) to 54 (hepatitis C treatments). The “unmanaged uptake” assumption (removed from ICER's approach in 2017) yields large deviations between BIM estimates and real-world consumption. Nevertheless, in some cases, ICER's BIMs that relied on current market estimates also deviated substantially from real-world sales data.Conclusions
This study highlights challenges with forecasting budget impact. In particular, assumptions about uptake and data source selection can greatly influence the accuracy of results. 相似文献6.
Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma of the skin, for which the exact mechanisms of carcinogenesis remain unknown. Therapeutic options for this highly aggressive malignancy have historically been limited in both their initial response and response durability. Recent improvements in our understanding of MCC tumor biology have expanded therapeutic options for these patients, namely through the use of immunotherapies such as immune checkpoint inhibitors. Further elucidation of the tumor mutational landscape has identified molecular targets for therapies, which have demonstrated success in other cancer types. In this review, we discuss both current and investigational immune and molecular targets of therapy for MCC. 相似文献
7.
8.
9.
Sara Meril Ortal Harush Yishai Reboh Tatyana Matikhina Tilda Barliya Cyrille J. Cohen 《Molecular carcinogenesis》2020,59(7):713-723
Chimeric antigen receptor (CAR) T-cells treatment demonstrate the increasing and powerful potential of immunotherapeutic strategies, as seen mainly for hematological malignancies. Still, efficient CAR-T cell approaches for the treatment of a broader spectrum of tumors are needed. It has been shown that cancer cells can implement strategies to evade immune response that include the expression of inhibitory ligands, such as hypersialylated proteins (sialoglycans) on their surface. These may be recognized by sialic acid-binding immunoglobulin-type lectins (siglecs) which are surface receptors found primarily on immune cells. In this regard, siglec-7 and -9 are found on immune cells, such as natural killer cells, T-cells, and dendritic cells and they can promote immune suppression when binding to sialic acids expressed on target cells. In the present study, we hypothesized that it is possible to use genetically engineered T-cells expressing siglec-based CARs, enabling them to recognize and eliminate tumor cells, in a non-histocompatibility complex molecule restricted way. Thus, we genetically modified human T-cells with different chimeric receptors based on the exodomain of human siglec-7 and -9 molecules and selected optimal receptors. We then assessed their antitumor activity in vitro demonstrating the recognition of cell lines from different histologies. These results were confirmed in a tumor xenograft model exemplifying the potential of the present approach. Overall, this study demonstrates the benefit of targeting cancer-associated glycosylation patterns using CAR based on native immune receptors and expressed in human primary T-cells. 相似文献
10.